ILF3 and neoplasm: To explore whether the ILF3–SGOC axis contributes to the capacity of tumor formation, we established two more patient-relevant models, patient-derived organoids (PDO) and patient-derived xenografts (PDX).47 We cultured organoids in vitro and found that knockdown of ILF3 expression with siILF3 significantly reduced organoid formation (Fig. 7a).